BRIEF-Bristol says Apixaban data adequate to seek U.S. regulatory approval

June 15 (Reuters) - Bristol-Myers Squibb Co:

* CEO says recent trial data on apixaban blood clot preventer, which compared it to aspirin, would be adequate to seek U.S. regulatory approval.

* Says Apixaban's higher efficacy than aspirin would be big advantage to the 30

to 40 percent of patients that cannot tolerate warfarin, the most widely used pill to prevent blood clots. Such patients rely instead on aspirin, which is less effective than warfarin in preventing clots.

((New York Equities Desk; tel: [phone]))

(For more news about Bristol-Myers Squibb Co click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.